A2AR PAM
Inflammatory/Autoimmune Diseases
Hit-to-LeadActive
Key Facts
About Adoram Therapeutics
Adoram Therapeutics is a preclinical-stage biotech company developing allosteric small molecule drugs targeting G-protein-coupled receptors (GPCRs), with a primary focus on immuno-oncology and inflammation. Its lead asset is an A2AR NAM for solid tumors, demonstrating promising preclinical data and nearing clinical candidate stage. The company possesses a proprietary allosteric screening technology and a licensed portfolio, aiming to build a multi-asset pipeline through internal R&D and strategic partnerships.
View full company profileTherapeutic Areas
Other Inflammatory/Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| BionicMimics™ Platform | Scinai Immunotherapeutics | Discovery |
| Undisclosed Immunometabolism Program(s) | Inapill | Preclinical |
| NAV-242 | Navigator Medicines | Phase 1 |
| CAN10 | Cantargia | Phase I (Completed) |
| CAN14 | Cantargia | Preclinical |